A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

NCT06754501 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Cancer

Interventions

DRUG: Atezolizumab
DRUG: Tiragolumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]